☆ 4.2 Editorial Material

Next Generation MRD

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)

Journal

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Volume 20, Issue 9, Pages 1259-1260

Publisher

ELSEVIER SCIENCE INC

DOI: 10.1016/j.bbmt.2014.07.002

Keywords

-

Categories

Hematology Immunology Transplantation

Funding

Intramural NIH HHS [ZIA HL006163-01] Funding Source: Medline

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Hematology

Next-generation sequencing-based MRD in adults with ALL undergoing hematopoietic cell transplantation

Emily C. Liang, Simone E. Dekker, Jean M. G. Sabile, Stefan Torelli, Amy Zhang, Katharine Miller, Parveen Shiraz, Brandon Hayes-Lattin, Jessica T. Leonard, Lori Muf

Summary: The prognostic value of NGS-based MRD in adult patients with ALL undergoing HCT has been minimally studied. This study evaluated the prognostic value of NGS-based MRD in adult patients with ALL undergoing HCT and found that NGS detection of MRD offers significant prognostic value in adults with ALL undergoing HCT.

BLOOD ADVANCES (2023)

Add to Collection

Review Oncology

Next-generation sequencing for MRD monitoring in B-lineage malignancies: from bench to bedside

Xinyue Deng, Meilan Zhang, Jianfeng Zhou, Min Xiao

Summary: Minimal residual disease (MRD) is the strongest predictor of prognosis and a crucial factor in treatment decisions for hematological malignancies. Advances in new strategies have resulted in deeper responses in patients, making it challenging for the widely used gold-standard techniques of MRD monitoring. High-throughput technologies, such as next-generation sequencing (NGS)-based clonality assays, are recommended as disease-monitoring modalities due to their sensitivity and ability to provide sufficient information.

EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2022)

Add to Collection

Article Hematology

High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse

Nicholas J. Short, Hagop Kantarjian, Farhad Ravandi, Marina Konopleva, Nitin Jain, Rashmi Kanagal-Shamanna, Keyur P. Patel, Walid Macaron, Tapan M. Kadia, Sa Wang, Jeffrey L. Jorgensen, Joseph D. Khoury, Musa Yilmaz, Partow Kebriaei, Koichi Takahashi, Guillermo Garcia-Manero, Naval Daver, Sean M. Post, Xuelin Huang, Steven M. Kornblau, Sara Pelletier, Wilmer Flores, Jairo Matthews, Rebecca Garris, Elias Jabbour

Summary: This study evaluated the clinical impact of a highly sensitive next-generation sequencing (NGS) MRD assay in acute lymphoblastic leukemia (ALL) patients. The study found that NGS detection could identify patients with a significant risk of relapse, even if they were considered MRD negative by multiparameter flow cytometry (MFC). Early assessment of MRD using NGS provides important prognostic information for predicting relapse risk and long-term survival in ALL patients.

BLOOD ADVANCES (2022)

Add to Collection

Article Hematology

Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations

Michael Heuser, Bennet Heida, Konstantin Buettner, Clara Philine Wienecke, Katrin Teich, Carolin Funke, Maximilian Brandes, Piroska Klement, Alessandro Liebich, Martin Wichmann, Blerina Neziri, Anuhar Chaturvedi, Arnold Kloos, Konstantinos Mintzas, Verena Gaidzik, Peter Paschka, Lars Bullinger, Walter Fiedler, Albert Heim, Wolfram Puppe, Juergen Krauter, Konstanze Doehner, Hartmut Doehner, Arnold Ganser, Michael Stadler, Lothar Hambach, Razif Gabdoulline, Felicitas Thol

Summary: Non-DTA mutations serve as prognostic NGS-MRD markers post-alloHCT in patients with acute myeloid leukemia, while MRD positivity is an independent adverse predictor of relapse, relapse-free survival, and overall survival.

BLOOD ADVANCES (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Next generation flow cytometry for MRD detection in patients with AL amyloidosis

Esftathios Kastritis, Ioannis Kostopoulos, Foteini Theodorakakou, Despina Fotiou, Maria Gavriatopoulou, Magdalini Migkou, Maria Irini Tselegkidi, Maria Roussou, Alexandra Papathoma, Evangelos Eleutherakis-Papaioakovou, Ioanna Dialoupi, Nikolaos Kanellias, Argyrios Ntalianis, Pantelis Rousakis, Ioannis P. Trougakos, Ourania Tsitsilonis, Charikleia Gakiopoulou, Evangelos Terpos, Meletios A. Dimopoulos

Summary: Detection of MRD using NGF has significant clinical implications for the treatment and prognosis of AL amyloidosis patients. Patients with undetectable MRD have a higher probability of organ response and a lower probability of hematologic relapse.

AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2021)

Add to Collection

Article Biochemical Research Methods

NGSNGS: next-generation simulator for next-generation sequencing data

Rasmus Amund Henriksen, Lei Zhao, Thorfinn Sand Korneliussen

Summary: This article presents a multithreaded simulator for next-generation sequencing data, which can simulate reads faster than currently available methods and programs. It can simulate reads with platform-specific characteristics based on nucleotide quality score profiles and includes a post-mortem damage model for simulating ancient DNA. The program is implemented in a multithreading framework and is significantly faster than currently available tools, while also offering additional features and output formats.

BIOINFORMATICS (2023)

Add to Collection

Review Chemistry, Physical

Next-generation cancer organoids

Bauer L. LeSavage, Riley A. Suhar, Nicolas Broguiere, Matthias P. Lutolf, Sarah C. Heilshorn

Summary: The translation discusses how organotypic models of patient-specific tumors are changing our understanding of cancer heterogeneity and personalized medicine. These models can preserve genetic, proteomic, morphological, and pharmacotypic features of the parent tumor in vitro, and offer genomic and environmental manipulation. However, current cancer organoid culture techniques are uncontrolled and irreproducible, hindering the acceleration of insights into patient care.

NATURE MATERIALS (2022)

Add to Collection

Editorial Material Plant Sciences

Next generation editors

John E. Lunn

Summary: The Journal of Experimental Botany has appointed six early career researchers as editorial interns to train the next generation of editors.

JOURNAL OF EXPERIMENTAL BOTANY (2023)

Add to Collection

Article Oncology

Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients

Rodrigo Fonseca, Mariano Arribas, Julia E. E. Wiedmeier-Nutor, Yael N. N. Kusne, Miguel Gonzalez Velez, Heidi E. E. Kosiorek, Richard (Duke) J. Butterfield, Ilan R. R. Kirsch, Joseph R. R. Mikhael, A. Keith Stewart, Craig Reeder, Jeremy Larsen, P. Leif Bergsagel, Rafael Fonseca

Summary: Minimal residual disease (MRD) assays allow assessment of treatment response in multiple myeloma (MM) patients, and achieving MRD negativity is associated with improved survival outcomes. The combination of highly sensitive next generation sequencing (NGS) MRD with functional imaging requires further validation. In this retrospective analysis of MM patients who underwent autologous stem cell transplant (ASCT), MRD negativity at day 100 post-ASCT was found to be the strongest prognostic indicator for longer time to next treatment (TTNT). The agreement between positron emission tomography (PET-CT) and MRD was poor, with high rates of PET-CT negativity in MRD-positive patients. Sustained MRD negativity was associated with longer TTNT regardless of baseline risk characteristics.

BLOOD CANCER JOURNAL (2023)

Add to Collection

Editorial Material Biochemical Research Methods

Next-generation expansion microscopy

Rita Strack

Summary: A new expansion microscopy technique called Magnify utilizes a mechanically robust gel to both immobilize and enlarge various biological samples for super-resolution imaging.

NATURE METHODS (2023)

Add to Collection

Article Multidisciplinary Sciences

Next generation reservoir computing

Daniel J. Gauthier, Erik Bollt, Aaron Griffith, Wendson A. S. Barbosa

Summary: Reservoir computers are artificial neural networks that can be trained on small data sets with large random matrices and numerous metaparameters. Nonlinear vector autoregression is a superior machine learning algorithm compared to reservoir computing, requiring fewer training data sets and training time.

NATURE COMMUNICATIONS (2021)

Add to Collection

Editorial Material Neurosciences

Next-generation brain observatories

Christof Koch, Karel Svoboda, Amy Bernard, Michele A. Basso, Anne K. Churchland, Adrienne L. Fairhall, Peter A. Groblewski, Jerome A. Lecoq, Zachary F. Mainen, Mackenzie W. Mathis, Shawn R. Olsen, John W. Phillips, Alexandre Pouget, Shreya Saxena, Josh H. Siegle, Anthony M. Zador

Summary: This article proposes the establishment of centralized brain observatories for large-scale recordings of neural activity in animals, aiming to advance reproducible systems neuroscience and democratize access to advanced tools and data.

NEURON (2022)

Add to Collection

Editorial Material Biochemical Research Methods

Next-generation single virus tracking

Sergi Padilla-Parra

Summary: Multiplexing real-time single virus tracking with imaging opens up new possibilities for studying virus-host interactions in detail, potentially leading to a paradigm shift.

NATURE METHODS (2022)

Add to Collection

Review Engineering, Biomedical

Next-generation personalized cranioplasty treatment

Bikramjit Basu, Jeyapriya Thimukonda Jegadeesan, Manish Baldia

Summary: Decompressive craniectomy (DC) is commonly used to treat various brain disorders, while cranioplasty surgery restores cranial symmetry and cosmetic outcomes. The manufacturing of patient-specific implants has shifted towards biomolecules and cellular-based methods. Despite advancements in 3D printing and image processing, the clinical procedure is time-consuming and costly. Therefore, automated implant fabrication using data-driven methods can accelerate the design and manufacturing of patient-specific cranial implants, providing predictable clinical outcomes.

ACTA BIOMATERIALIA (2022)

Add to Collection

Article Biotechnology & Applied Microbiology

The chemistry of next-generation sequencing

Raphael Rodriguez, Yamuna Krishnan

Summary: This article reviews the historical development of next-generation sequencing chemistry, highlighting the significant impact of the underlying chemical principles on biology.

NATURE BIOTECHNOLOGY (2023)

Add to Collection

Article Hematology

Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study

Nelli Bejanyan, Meijie Zhang, Khalid Bo-Subait, Claudio Brunstein, Hailin Wang, Erica D. Warlick, Sergio Giralt, Taiga Nishihori, Rodrigo Martino, Jakob Passweg, Ajoy Dias, Edward Copelan, Gregory Hale, Robert Peter Gale, Melhem Solh, Mohamed A. Kharfan-Dabaja, Miguel Angel Diaz, Siddhartha Ganguly, Steven Gore, Leo F. Verdonck, Nasheed M. Hossain, Natasha Kekre, Bipin Savani, Michael Byrne, Christopher Kanakry, Mitchell S. Cairo, Stefan Ciurea, Harry C. Schouten, Christopher Bredeson, Reinhold Munker, Hillard Lazarus, Jean-Yves Cahn, Marjolein van der Poel, David Rizzieri, Jean A. Yared, Cesar Freytes, Jan Cerny, Mahmoud Aljurf, Neil D. Palmisiano, Attaphol Pawarode, Vera Ulrike Bacher, Michael R. Grunwald, Sunita Nathan, Baldeep Wirk, Gerhard C. Hildebrandt, Sachiko Seo, Richard F. Olsson, Biju George, Marcos de Lima, Christopher S. Hourigan, Brenda M. Sandmaier, Mark Litzow, Partow Kebriaei, Wael Saber, Daniel Weisdorf

Summary: Myeloablative conditioning is preferable for AML/MDS patients with low/intermediate-risk DRI, while both MAC and RIC show similar benefits in patients with high/very high-risk DRI. Novel MAC regimens with less toxicity are beneficial for all patients, but more potent antineoplastic approaches are needed for the high/very-high risk DRI group.

TRANSPLANTATION AND CELLULAR THERAPY (2021)

Add to Collection

Editorial Material Hematology

Detectable mutations precede late myeloid neoplasia in aplastic anemia

Bhavisha A. Patel, Jack Ghannam, Emma M. Groarke, Meghali Goswami, Laura Dillon, Fernanda Gutierrez-Rodrigues, Olga Rios, Diego Quinones Raffo, Jennifer Lotter, Neal S. Young, Christopher S. Hourigan

HAEMATOLOGICA (2021)

Add to Collection

Letter Oncology

Measurable Residual Disease Before Reduced-Intensity Allogeneic Transplantation in Patients With Myeloid Malignancy

Gege Gui, Laura W. Dillon, Christopher S. Hourigan

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Review Oncology

Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations

Roland B. Walter, Yishai Ofran, Agnieszka Wierzbowska, Farhad Ravandi, Christopher S. Hourigan, Lok Lam Ngai, Adriano Venditti, Francesco Buccisano, Gert J. Ossenkoppele, Gail J. Roboz

Summary: MRD testing in AML is an important biomarker for predicting patient outcomes and early detection of relapse. However, there are still open questions regarding the optimal timing and frequency of testing, as well as defining thresholds for relapse. Studies confirming the direct impact of treatment effects on MRD to clinical outcomes are needed to establish MRD as a surrogate endpoint in AML.

LEUKEMIA (2021)

Add to Collection

Review Multidisciplinary Sciences

Intensive versus less-intensive antileukemic therapy in older adults with acute myeloid leukemia: A systematic review

Yaping Chang, Gordon H. Guyatt, Trevor Teich, Jamie L. Dawdy, Shaneela Shahid, Jessica K. Altman, Richard M. Stone, Mikkael A. Sekeres, Sudipto Mukherjee, Thomas W. LeBlanc, Gregory A. Abel, Christopher S. Hourigan, Mark R. Litzow, Laura C. Michaelis, Shabbir M. H. Alibhai, Pinkal Desai, Rena Buckstein, Janet MacEachern, Romina Brignardello-Petersen

Summary: The study compared the effectiveness and safety of intensive antileukemic therapy to less-intensive therapy in older adults with acute myeloid leukemia, and found that intensive therapy may lead to longer survival and higher probability of receiving allogeneic hematopoietic stem cell transplantation, but also increase the risk of severe, treatment-emergent adverse events and longer duration of intensive care unit hospitalization.

PLOS ONE (2021)

Add to Collection

Article Hematology

Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML

Kamal Menghrajani, Alexandra Gomez-Arteaga, Rafael Madero-Marroquin, Mei-Jie Zhang, Khalid Bo-Subait, Jonathan Sanchez, Hai-Lin Wang, Mahmoud Aljurf, Amer Assal, Vera Ulrike Bacher, Sherif M. Badawy, Nelli Bejanyan, Vijaya Raj Bhatt, Christopher Bredeson, Michael Byrne, Paul Castillo, Jan Cerny, Saurabh Chhabra, Stefan Octavian Ciurea, Zachariah DeFilipp, Nosha Farhadfar, Shahinaz Gadalla, Robert Peter Gale, Siddhartha Ganguly, Lohith Gowda, Michael R. Grunwald, Shahrukh Hashmi, Gerhard Hildebrandt, Christopher G. Kanakry, Ankit Kansagra, Farhad Khimani, Maxwell Krem, Hillard Lazarus, Hongtao Liu, Rodrigo Martino, Fotios Michelis, Sunita Nathan, Taiga Nishihori, Richard Olsson, Ran Reshef, David Rizzieri, Jacob M. Rowe, Bipin N. Savani, Sachiko Seo, Akshay Sharma, Melhem Solh, Celalettin Ustun, Leo F. Verdonck, Christopher Hourigan, Brenda Sandmaier, Mark Litzow, Partow Kebriaei, Daniel Weisdorf, Yanming Zhang, Martin S. Tallman, Wael Saber

Summary: This study aimed to evaluate the predictive ability of risk classification at diagnosis for post-HCT outcomes in AML patients. The results showed that patients with KMT2A rearrangement or adverse-risk AML had a higher risk of relapse compared to those with intermediate-risk disease, but had similar leukemia-free survival and overall survival rates. Additionally, no differences in outcome were observed when patients were stratified by KMT2A fusion partner.

BLOOD ADVANCES (2022)

Add to Collection

Article Hematology

Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia

Matthew J. Wieduwilt, Leland Metheny, Mei-Jie Zhang, Hai-Lin Wang, Noel Estrada-Merly, David Marks, A. Samer Al-Homsi, Lori Muffly, Nelson Chao, David Rizzieri, Robert Peter Gale, Shahinaz M. Gadalla, Mitchell Cairo, Alberto Mussetti, Steven Gore, Vijaya Raj Bhatt, Sagar S. Patel, Fotios Michelis, Yoshihiro Inamoto, Sherif M. Badawy, Edward Copelan, Neil Palmisiano, Mohamed A. Kharfan-Dabaja, Hillard M. Lazarus, Siddhartha Ganguly, Christopher Bredeson, Miguel Angel Diaz Perez, Ryan Cassaday, Bipin N. Savani, Karen Ballen, Rodrigo Martino, Baldeep Wirk, Ulrike Bacher, Mahmoud Aljurf, Asad Bashey, Hemant S. Murthy, Jean A. Yared, Ibrahim Aldoss, Nosha Farhadfar, Hongtao Liu, Hisham Abdel-Azim, Edmund K. Waller, Melhem Solh, Matthew D. Seftel, Marjolein van der Poel, Michael R. Grunwald, Jane L. Liesveld, Rammurti T. Kamble, Joseph McGuirk, Reinhold Munker, Jean-Yves Cahn, Jong Wook Lee, Cesar O. Freytes, Maxwell M. Krem, Lena E. Winestone, Usama Gergis, Sunita Nathan, Richard F. Olsson, Leo F. Verdonck, Akshay Sharma, Olle Ringden, Brian D. Friend, Jan Cerny, Hannah Choe, Saurabh Chhabra, Taiga Nishihori, Sachiko Seo, Biju George, Lee Ann Baxter-Lowe, Gerhard C. Hildebrandt, Marcos de Lima, Mark Litzow, Partow Kebriaei, Christopher S. Hourigan, Muhammad Bilal Abid, Daniel J. Weisdorf, Wael Saber

Summary: This study compared the outcomes of haploidentical hematopoietic cell transplantation (HCT) using posttransplant cyclophosphamide (PTCy) with other HCT approaches for acute lymphoblastic leukemia (ALL) patients. The results showed that haploidentical HCT using PTCy had similar overall survival (OS) but lower incidence of chronic graft-versus-host disease (cGVHD) compared to traditional matched sibling and unrelated donor HCT methods, making it a preferred alternative donor option for ALL patients in complete remission.

BLOOD ADVANCES (2022)

Add to Collection

Review Oncology

Measurable Residual Disease Assessment as a Surrogate Marker in New Drug Development in Acute Myeloid Leukemia

Gege Gui, Christopher S. Hourigan

Summary: Response criteria based on cytomorphology for AML patients are inadequate. Higher sensitivity measures of residual disease burden can predict relapse rates and survival outcomes more accurately. However, the heterogeneous genetic etiology and immunophenotypic profiles of AML make the development of standardized and validated MRD assessments challenging.

CANCER JOURNAL (2022)

Add to Collection

Article Hematology

Utility of plasma cell-free DNA for de novo detection and quantification of clonal hematopoiesis

Fernanda Gutierrez-Rodrigues, Isabel Beerman, Emma M. Groarke, Bhavisha A. Patel, Nina Spitofsky, Laura W. Dillon, Diego Quinones Raffo, Christopher S. Hourigan, Sachiko Kajigaya, Luigi Ferrucci, Neal S. Young

Summary: cfDNA tests can be used to monitor clonal hematopoiesis in hematologic diseases, but they have poor concordance with blood cells in diseases with low allele burdens or in healthy individuals.

HAEMATOLOGICA (2022)

Add to Collection

Article Oncology

Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia

Meghali Goswami, Gege Gui, Laura W. Dillon, Katherine E. Lindblad, Julie Thompson, Janet Valdez, Dong-Yun Kim, Jack Y. Ghannam, Karolyn A. Oetjen, Christin B. Destefano, Dana M. Smith, Hanna Tekleab, Yeusheng Li, Pradeep Dagur, Thomas Hughes, Jennifer L. Marte, Jaydira del Rivero, Joanna Klubo-Gwiezdzinksa, James L. Gulley, Katherine R. Calvo, Catherine Lai, Christopher S. Hourigan

Summary: This study aimed to investigate the feasibility and efficacy of the combination of PD-1 blockade and hypomethylating therapy in patients with R-AML. The results showed that this combination therapy achieved disease stability or better response in some patients. Moreover, clonal T cell expansions and immunological changes were observed during treatment, which may be associated with treatment-related adverse events.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection

Article Biophysics

Age is no barrier for adults undergoing HCT for AML in CR1: contemporary CIBMTR analysis

Joseph E. Maakaron, Mei-Jie Zhang, Karen Chen, Sunil Abhyankar, Vijaya Raj Bhatt, Saurabh Chhabra, Najla El Jurdi, Sherif S. Farag, Fiona He, Mark Juckett, Marcos de Lima, Navneet Majhail, Marjolein van der Poel, Ayman Saad, Bipin Savani, Celalettin Ustun, Edmund K. Waller, Mark Litzow, Partow Kebriaei, Christopher S. Hourigan, Wael Saber, Daniel Weisdorf

Summary: A study on 1321 AML patients aged 60 and older found that age alone is not a barrier to successful HCT in CR1, and efforts should focus on minimizing residual disease and better donor selection.

BONE MARROW TRANSPLANTATION (2022)

Add to Collection

Article Oncology

Integrative analysis of drug response and clinical outcome in acute myeloid leukemia

Daniel Bottomly, Nicola Long, Anna Reister Schultz, Stephen E. Kurtz, Cristina E. Tognon, Kara Johnson, Melissa Abel, Anupriya Agarwal, Sammantha Avaylon, Erik Benton, Aurora Blucher, Uma Borate, Theodore P. Braun, Jordana Brown, Jade Bryant, Russell Burke, Amy Carlos, Bill H. Chang, Hyun Jun Cho, Stephen Christy, Cody Coblentz, Aaron M. Cohen, Amanda d'Almeida, Rachel Cook, Alexey Danilov, Kim-Hien T. Dao, Michie Degnin, James Dibb, Christopher A. Eide, Isabel English, Stuart Hagler, Heath Harrelson, Rachel Henson, Hibery Ho, Sunil K. Joshi, Brian Junio, Andy Kaempf, Yoko Kosaka, Ted Laderas, Matt Lawhead, Hyunjung Lee, Jessica T. Leonard, Chenwei Lin, Evan F. Lind, Selina Qiuying Liu, Pierrette Lo, Marc M. Loriaux, Samuel Luty, Julia E. Maxson, Tara Macey, Jacqueline Martinez, Jessica Minnier, Andrea Monteblanco, Motomi Mori, Quinlan Morrow, Dylan Nelson, Justin Ramsdill, Angela Rofelty, Alexandra Rogers, Kyle A. Romine, Peter Ryabinin, Jennifer N. Saultz, David A. Sampson, Samantha L. Savage, Robert Schuff, Robert Searles, Rebecca L. Smith, Stephen E. Spurgeon, Tyler Sweeney, Ronan T. Swords, Aashis Thapa, Karina Thiel-Klare, Elie Traer, Jake Wagner, Beth Wilmot, Joelle Wolf, Guanming Wu, Amy Yates, Haijiao Zhang, Christopher R. Cogle, Robert H. Collins, Michael W. Deininger, Christopher S. Hourigan, Craig T. Jordan, Tara L. Lin, Micaela E. Martinez, Rachel R. Pallapati, Daniel A. Pollyea, Anthony D. Pomicter, Justin M. Watts, Scott J. Weir, Brian J. Druker, Shannon K. McWeeney, Jeffrey W. Tyner

Summary: This report presents findings from a large cohort of AML patients, combining genomic, transcriptomic, and clinical data to uncover associations between drug sensitivity, cell differentiation state, and patient survival prediction.

CANCER CELL (2022)

Add to Collection

Letter Hematology

Increased incidence of hematologic malignancies in SCD after HCT in adults with graft failure and mixed chimerism

Rialnat A. Lawal, Devdeep Mukherjee, Emily M. Limerick, Wynona Coles, Matthew M. Hsieh, Laura W. Dillon, Christopher S. Hourigan, Courtney D. Fitzhugh

BLOOD (2022)

Add to Collection

Review Hematology

How I treat AML incorporating the updated classifications and guidelines

Firas El Chaer, Christopher S. Hourigan, Amer M. Zeidan

Summary: The European LeukemiaNet has recently updated the clinical and measurable residual disease testing guidelines for acute myeloid leukemia (AML) in 2022 and 2021 respectively. These updates provide new recommendations for classification, risk stratification, prognostication, monitoring, and response assessment in AML patients. Advances in understanding the genetic drivers of AML and its biology have led to the development of novel therapies and more complex clinical treatment guidelines.

BLOOD (2023)

Add to Collection

Article Hematology

Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults

Leland Metheny, Natalie S. Callander, Aric C. Hall, Mei-Jei Zhang, Khalid Bo-Subait, Hai-Lin Wang, Vaibhav Agrawal, A. Samer Al-Homsi, Amer Assal, Ulrike Bacher, Amer Beitinjaneh, Nelli Bejanyan, Vijaya Raj Bhatt, Chris Bredeson, Michael Byrne, Mitchell Cairo, Jan Cerny, Zachariah DeFilipp, Miguel Angel Diaz Perez, Esar O. Freytes, Siddhartha Ganguly, Michael R. Grunwald, Shahrukh Hashmi, Gerhard C. Hildebrandt, Yoshihiro Inamoto, Christopher G. Kanakry, Mohamed A. Kharfan-Dabaja, Hillard M. Lazarus, Jong Wook Lee, Sunita Nathan, Taiga Nishihori, Richard F. Olsson, Olov Ringden, David Rizzieri, Bipin N. Savani, Mary Lynn Savoie, Sachiko Seo, Marjolein van der Poel, Leo F. Verdonck, John L. Wagner, Jean A. Yared, Christopher S. Hourigan, Partow Kebriaei, Mark Litzow, Brenda M. Sandmaier, Wael Saber, Daniel Weisdorf, Marcos de Lima

Summary: The prognosis for patients with therapy-related myeloid neoplasm, including myelodysplastic syndrome (t-MDS) and acute myelogenous leukemia (t-AML), is poor. Although modern supportive care and conditioning regimens have improved outcomes, the major cause of treatment failure remains relapse. Caution is advised when recommending allogeneic hematopoietic cell transplantation, and more effective antineoplastic approaches are needed.

TRANSPLANTATION AND CELLULAR THERAPY (2021)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.